Prof Martine Piccart gives a press conference at the 2019 San Antonio Breast Cancer Symposium about the update data from the APHINITY trial which investigated the addition of pertuzumab to trastuzumab plus chemotherapy in patients with operable HER2-positive early breast cancer.
Sign up to ecancer for free to receive tailored email alerts for more videos like this.
ecancer.org/account/register.php
